These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 15914550)

  • 1. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer.
    Rouzier R; Rajan R; Wagner P; Hess KR; Gold DL; Stec J; Ayers M; Ross JS; Zhang P; Buchholz TA; Kuerer H; Green M; Arun B; Hortobagyi GN; Symmans WF; Pusztai L
    Proc Natl Acad Sci U S A; 2005 Jun; 102(23):8315-20. PubMed ID: 15914550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microtubule Associated Protein (MAP)-Tau: a novel mediator of paclitaxel sensitivity in vitro and in vivo.
    Wagner P; Wang B; Clark E; Lee H; Rouzier R; Pusztai L
    Cell Cycle; 2005 Sep; 4(9):1149-52. PubMed ID: 16103753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
    Andre F; Mazouni C; Liedtke C; Kau SW; Frye D; Green M; Gonzalez-Angulo AM; Symmans WF; Hortobagyi GN; Pusztai L
    Breast Cancer Res Treat; 2008 Mar; 108(2):183-90. PubMed ID: 17468948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microtubule-associated protein tau correlates with estrogen receptor status but not with in vitro paclitaxel sensitivity in primary breast cancer.
    Honig A; Gehrmann M; Kranke P; Keller D; Engel JB; Hengstler S; Schmidt M
    Eur J Gynaecol Oncol; 2014; 35(5):503-7. PubMed ID: 25423693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer.
    Andre F; Hatzis C; Anderson K; Sotiriou C; Mazouni C; Mejia J; Wang B; Hortobagyi GN; Symmans WF; Pusztai L
    Clin Cancer Res; 2007 Apr; 13(7):2061-7. PubMed ID: 17404087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer.
    Liu XY; Jiang W; Ma D; Ge LP; Yang YS; Gou ZC; Xu XE; Shao ZM; Jiang YZ
    Theranostics; 2020; 10(24):10940-10956. PubMed ID: 33042263
    [No Abstract]   [Full Text] [Related]  

  • 7. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. +TIP EB1 downregulates paclitaxel‑induced proliferation inhibition and apoptosis in breast cancer cells through inhibition of paclitaxel binding on microtubules.
    Thomas GE; Sreeja JS; Gireesh KK; Gupta H; Manna TK
    Int J Oncol; 2015 Jan; 46(1):133-46. PubMed ID: 25310526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer.
    Esteva FJ; Wang J; Lin F; Mejia JA; Yan K; Altundag K; Valero V; Buzdar AU; Hortobagyi GN; Symmans WF; Pusztai L
    Breast Cancer Res; 2007; 9(6):R87. PubMed ID: 18086299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarker analysis of neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or Paclitaxel in early-stage breast cancer.
    Horak CE; Pusztai L; Xing G; Trifan OC; Saura C; Tseng LM; Chan S; Welcher R; Liu D
    Clin Cancer Res; 2013 Mar; 19(6):1587-95. PubMed ID: 23340299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer.
    Khongkow M; Olmos Y; Gong C; Gomes AR; Monteiro LJ; Yagüe E; Cavaco TB; Khongkow P; Man EP; Laohasinnarong S; Koo CY; Harada-Shoji N; Tsang JW; Coombes RC; Schwer B; Khoo US; Lam EW
    Carcinogenesis; 2013 Jul; 34(7):1476-86. PubMed ID: 23514751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationships between the chemosensitivity of human gastric cancer to paclitaxel and the expressions of class III β-tubulin, MAPT, and survivin.
    He W; Zhang D; Jiang J; Liu P; Wu C
    Med Oncol; 2014 May; 31(5):950. PubMed ID: 24722794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of βIII-tubulin expression as a predictive marker.
    Saura C; Tseng LM; Chan S; Chacko RT; Campone M; Manikhas A; Nag SM; Leichman CG; Dasappa L; Fasching PA; Hurtado de Mendoza F; Symmans WF; Liu D; Mukhopadhyay P; Horak C; Xing G; Pusztai L
    Oncologist; 2013; 18(7):787-94. PubMed ID: 23853246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen receptor-α directly regulates sensitivity to paclitaxel in neoadjuvant chemotherapy for breast cancer.
    Tokuda E; Seino Y; Arakawa A; Saito M; Kasumi F; Hayashi S; Yamaguchi Y
    Breast Cancer Res Treat; 2012 Jun; 133(2):427-36. PubMed ID: 21909982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.
    Hess KR; Anderson K; Symmans WF; Valero V; Ibrahim N; Mejia JA; Booser D; Theriault RL; Buzdar AU; Dempsey PJ; Rouzier R; Sneige N; Ross JS; Vidaurre T; Gómez HL; Hortobagyi GN; Pusztai L
    J Clin Oncol; 2006 Sep; 24(26):4236-44. PubMed ID: 16896004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer cell adaptation to chemotherapy.
    Di Nicolantonio F; Mercer SJ; Knight LA; Gabriel FG; Whitehouse PA; Sharma S; Fernando A; Glaysher S; Di Palma S; Johnson P; Somers SS; Toh S; Higgins B; Lamont A; Gulliford T; Hurren J; Yiangou C; Cree IA
    BMC Cancer; 2005 Jul; 5():78. PubMed ID: 16026610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-dimensional collagen type I matrix up-regulates nuclear isoforms of the microtubule associated protein tau implicated in resistance to paclitaxel therapy in ovarian carcinoma.
    Gurler H; Yu Y; Choi J; Kajdacsy-Balla AA; Barbolina MV
    Int J Mol Sci; 2015 Feb; 16(2):3419-33. PubMed ID: 25658796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial.
    Pusztai L; Jeong JH; Gong Y; Ross JS; Kim C; Paik S; Rouzier R; Andre F; Hortobagyi GN; Wolmark N; Symmans WF
    J Clin Oncol; 2009 Sep; 27(26):4287-92. PubMed ID: 19667268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinase shRNA screening reveals that TAOK3 enhances microtubule-targeted drug resistance of breast cancer cells via the NF-κB signaling pathway.
    Lai TC; Fang CY; Jan YH; Hsieh HL; Yang YF; Liu CY; Chang PM; Hsiao M
    Cell Commun Signal; 2020 Oct; 18(1):164. PubMed ID: 33087151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of centrosomal protein Nlp confers breast carcinoma resistance to paclitaxel.
    Zhao W; Song Y; Xu B; Zhan Q
    Cancer Biol Ther; 2012 Feb; 13(3):156-63. PubMed ID: 22353935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.